Novartis has opened an investigation after learning that a company employee was affiliated with a study of its blood pressure drug Diovan as a statistician without revealing his ties to the Swiss healthcare giant.
While the U.S. government was announcing its kickbacks lawsuit against Novartis, the Swiss drugmaker was putting the finishing touches on a few press releases of its own.
Here's a multibillion-dollar question: With their improved cash positions, will pharma companies increase spending this year on acquisitions? Over at Moody's, analysts predict that the answer to this question will be "yes" and deep-pocketed pharma companies will spend big dollars on M&A deals.
And Pfizer plans to relocate most of its 530 employees from its operations in the Alewife section of Cambridge closer to where about 400 of the pharma giant's employees are working in Kendall Square, The Boston Globe reported.
In recent months Proteon has completed a Phase II study for its lead vessel-dilating candidate PRT-201, advancing the program to where Novartis can take its four-year-old option to gobble up the biotech outfit entirely.
Today two countries on opposite sides of the world took radically different stances on pharma patents that will have a big impact on the future of drug R&D.
Novartis notched an FDA approval on Friday for a dry-powder formulation of an antibiotic that fights a type of bacterial infection in patients with cystic fibrosis (CF).
Celgene has made a move into the resurgent gene therapy field. With a focus on immunotherapies against cancer, Celgene revealed collaborations with a pair of partners on Thursday that highlights increased industry interest in the previously shunned gene therapy field after a series of regulatory and scientific victories in recent years.
Add up the top-line R&D spending for the top 10 pharma companies in the world and you'd think that nothing had changed from 2011 to 2012. But you'd be very wrong. Big Pharma's heavy hitters in R&D have a wildly mixed record in a fast-changing field. It will be an interesting year ahead. Here's a look at last year's results, and an analysis of where they point. Read the report >>
The FDA has opened the inside track to Novartis' experimental lung cancer drug, which gained "Breakthrough Therapy" designation that speeds the development and review schedules for new treatments. The Swiss drug giant ($NVS) plans to file for approval the drug, now in mid-stage clinical trials, in early 2014.